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Abstract The objective of this study is to assess the genetic distribution of
Charcot-Marie-Tooth (CMT) disease in Campania, a region of Southern Italy. We analyzed
a cohort of 197 index cases and reported the type and frequency of mutations for the
whole CMT population and for each electrophysiological group (CMT1, CMT2, and heredi-
tary neuropathy with susceptibility to pressure palsies [HNPP]) and for familial and isolated
CMT cases. Genetic diagnosis was achieved in 148 patients (75.1%) with a higher success
rate in HNPP and CMT1 than CMT2. Only four genes (PMP22, GJB1, MPZ , and GDAP1)
accounted for 92% of all genetically confirmed CMT cases. In CMT1, PMP22 duplication
was the most common mutation while the second gene in order of frequency was MPZ
in familial and SH3TC2 in isolated cases. In CMT2, GJB1 was the most frequent mutated
gene andGJB1withGDAP1 accounted for almost 3/4 of genetically defined CMT2 patients.
The first gene in order of frequency was GJB1 in familial and GDAP1 in isolated cases. In
HNPP, themajority of patients harbored the PMP22 gene deletion. The novelty of our data is
the relatively high frequency of SH3TC2 and GDAP1mutations in demyelinating and axonal
forms, respectively. These epidemiological data can help in panel design for our patients’
population.
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Introduction
Charcot-Marie-Tooth (CMT) disease, also known
as Hereditary Sensory Motor Neuropathy, is the most
common neurologic hereditary disorder with a preva-
lence of about 1:2500. CMT shows a great variability
of inheritance (Autosomal Dominant/AD, Autosomal
Recessive/AR, X-linked, and mitochondrial), age of
onset, and clinical features. In most cases, it presents
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with progressive distal muscular atrophy and weak-
ness, distal sensory loss, decrease or absence of deep
tendon reflexes, and skeletal deformities as pes cavus
(Shy et al., 2005).
CMT is typically classified into two main groups
based on upper limb nerve conduction study (NCS) and
nerve pathology findings: demyelinating forms (CMT1
if AD, CMT4 if AR) show nerve conduction velocity
(NCV) ≤38m/s and pathologic evidence of nerve
fiber demyelination; axonal forms (CMT2) instead
have NCV >38m/s and pathologic features of axonal
degeneration and regeneration (Harding and Thomas,
1980). Moreover, it is possible to identify a third group,
called intermediate CMT, characterized by both myelin
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changes and axonal degeneration, and NCV between
25 and 45m/s overlapping the values of CMT1 and
CMT2 (Nicholson and Myers, 2006). Additionally, CMT
disease includes the hereditary neuropathy with sus-
ceptibility to pressure palsies (HNPP) that is typically
characterized by slowing of nerve conduction velocity
at the usual sites of entrapment (Andersson et al.,
2000).
Electrophysiological characterization plays a crucial
role in addressing the genetic testing. However, molec-
ular studies in the last years expanded the list of genes
involved in the disease and 80 CMT-associated genes
have now been discovered (Timmerman et al., 2014).
This broad genetic heterogeneity makes the diagnostic
procedure difficult in clinical practice. Thus, epidemio-
logical studies by evaluating the prevalence of different
genetic CMT subtypes can help to design diagnostic
flowchart to be used by clinicians in choosing genetic
testing.
Three studies in German (Gess et al., 2013),
English (Murphy et al., 2012) and American (Saporta
et al., 2011) populations have found that about 90%
of patients with genetically confirmed diagnosis of
CMT had a mutation in one of these four genes,
PMP22, GJB1, MPZ , and MFN2. However, a more
recent study developed in the Region of Valencia in
Spain reported a higher frequency of GDAP1 over
MFN2 gene (Sivera et al., 2013). This difference raises
the issue of the geographical area influence on CMT
genotype distribution.
To our knowledge there are few and outdated
(Guzzetta et al., 1995; Mostacciuolo et al., 1995;
Morocutti et al., 2002) epidemiologic data on CMT in
Italy and the aim of this study is to provide epidemio-
logic data from Campania, a region of Southern Italy
on the Mediterranean Sea. Therefore, we report the
genetic distribution in our cohort of CMT patients, for
the main CMT phenotypes (CMT1, CMT2, and HNPP).
Patients and Methods
This is a descriptive study, based on examination of
data from CMT patients evaluated from 1998 to 2013 in
a tertiary care neuromuscular center at the University
Federico II of Naples. Written informed consents were
obtained for genetic analysis from all patients included
in this study.
Patients were considered to have CMT if a senso-
rimotor neuropathy was present and the family history
was positive for a similar condition. Patients without
a positive family history (isolated) were considered to
have CMT if their neurological and neurophysiological
examination was typical for CMT and after excluding
causes for an acquired neuropathy (toxic, metabolic,
inflammatory, and infectious). Patients (index cases)
were classified as demyelinating (CMT1) or axonal
(CMT2) CMT, according to upper limb motor NCV.
Accordingly, patients were classified as CMT1 if motor
NCV was ≤38m/s (except when the amplitude of com-
pound muscle action potential was <0.5mV) and as
CMT2 if NCV was >38m/s.
CMT1 patients were firstly tested for PMP22
duplication of chromosome 17p11.2. When negative,
patients were then tested for GJB1 mutations (unless
evidence of male to male transmission in the family),
PMP22 point mutations, or MPZ mutations. Patients
with CMT1 were also screened for EGR2, NEFL,
GDAP1, LITAF , SH3TC2, FIG4, or CTDP1 mutations
where appropriate.
CMT2 patients were, at first, tested for GJB1
(unless male to male transmission in the family)
mutations. Then, MPZ , MFN2, and GDAP1 genes
were screened for mutations. Further, CMT2 patients
were tested for NEFL, GARS, TRPV4, RAB7, HSPB1,
HSPB8, SPTLC1, LMNAC, or HINT1 mutations where
appropriate.
Patients with a medical history of transient palsies
and/or sensory loss related to typical nerve compres-
sion points (pressure palsies), conduction blocks and/or
slowing of NCV at the usual sites of entrapment, were
considered for a clinical phenotype of HNPP. These
patients were tested for deletions of chromosome
17p11.2 and if negative, patients were screened for
point mutations in PMP22. In isolated cases in which a
mutation was found, we analyzed also both parents (if
available) confirming or excluding the de novo origin of
the genetic defect.
We calculated the type and frequency ofmutations
for thewhole CMT population and for each electrophys-
iological group (CMT1, CMT2, and HNPP). Moreover,
within each electrophysiological group we calculated
the type and frequency of genetic alterations for famil-
ial and isolated CMT cases and reported the number of
de novo mutations.
Results
A total of 197 index cases, having clinical and elec-
trophysiological features of CMT disease, were evalu-
ated in our clinic over 15 years. All patients were from
Campania. According to electrophysiological study, 109
patients (55.3%) were classified as CMT1, 55 patients
(28%) as CMT2, and 33 patients (16.7%) as HNPP
(Fig. 1). Genetic diagnosis was achieved in 148 patients
(75.1%) with a success rate in descending order in
HNPP (29/33: 87.8%), in demyelinating CMT (93/109:
85.3%), and in axonal CMT (26/55: 47.2%) (Fig. 1).
Mutations in 12 different genes and 12 novel mutations
were found (Table 1).
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Figure 1. Genetic characterization of Charcot-Marie-Tooth (CMT) disease subtypes. * denotes 3males and 1 female; # denotes
3 males and 7 females.
Patients with CMT1
In the 93 genetically diagnosed CMT1 probands,
we detected PMP22 duplication in 75, GJB1 and MPZ
mutations in 4, PMP22 in 3, SH3TC2 in 3, EGR2 in
2, NEFL and CTDP1 each in 1 patient. Six mutations
were novel: p.Leu78Pro and p.Gln103X (Pisciotta et al.,
2009) in PMP22, p.Tyr82Ser and p.Ser111Cys (Mandich
et al., 2009) in MPZ , and p.Glu1005X and p.Tyr1107X
in SH3TC2 (Table 1). The majority of CMTX patients
classified as having CMT1 were males (3/4: 75%).
Among the 93 genetically characterized CMT1
patients, 67 were familial and 26 isolated cases. In
familial cases, PMP22 duplication was found in 59
patients, MPZ mutations in 3, GJB1 and PMP22 in
2, and NEFL in 1 patient. In isolated cases, PMP22
duplication was found in 16 patients, SH3TC2 muta-
tions in 3, GJB1 and EGR2 in 2 and, PMP22,MPZ and
CTDP1 each in 1 patient (Fig. 1). Five mutations were
de novo: 1.5-Mb duplication in 17p11.2, p.Ser72Leu in
PMP22, p.Tyr82Ser inMPZ , p.Arg381His in EGR2, and
p.Ser26Leu in GJB1.
Patients with CMT2
In the 26 CMT2 probands with genetic diag-
nosis, we found GJB1 mutations in 10 patients,
GDAP1 in 8, MPZ in 3, MFN2 in 2 and, RAB7,
TRPV4, and HSPB1 each in 1 patient. Novel muta-
tions were found in GDAP1 (p.Arg120Gly; Manganelli
et al., 2012a, p.Asp129His, and p.Glu145fs) and in
MPZ (p.Asp109Glu) (Santoro et al., 2004) and GJB1
(p.Gln99dup) genes (Table 1). The majority of CMTX
patients classified as having CMT2 were females (7/10:
70%).
Among the 26 characterized CMT2 patients, 19
were familial and 7 isolated cases. In familial cases
GJB1 mutations were observed in 8 patients, GDAP1
in 4, MPZ in 3, and MFN2, RAB7, TRPV4, and HSPB1
each in 1 patient. In isolated cases, we found AR
GDAP1 mutations in 4 patients, GJB1 in 2, and MFN2
in 1 patient (Fig. 1). Two mutations were de novo:
p.Trp3Gly in GJB1 and p.Arg104Trp in MFN2.
Patients with HNPP
In the 29 characterized HNPP probands, we found
PMP22 deletion in 25 patients and PMP22 mutations
in 4 patients. One of these mutations was novel
(p.Trp39X) (Table 1). Among HNPP patients, 15 patients
were familial and 14 isolated cases. In familial cases,
we found PMP22 deletion in 13 patients and PMP22
mutation in 2 patients. In isolated cases, we found
PMP22 deletion in 12 patients and PMP22 mutations
in 2 patients (Fig. 1). One PMP22 deletion was a de
novo mutation.
Discussion
This study evaluates for the first time the fre-
quency of genetic subtypes of CMT patients in a
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Table 1. Details of gene alterations (without PMP22
duplication and deletion).
CMT subtype Gene Mutation
CMT1A PMP22 p.Leu78Pro
p.Gln103X
Dejerine-Sottàs PMP22 p.Ser72Leu
HNPP PMP22 p.Trp39X
p.Leu145fs
p.Leu145fs
p.Leu145fs
CMTX GJB1 p.Trp3Gly
p.Arg15Gln
p.Ser26Leu
p.Gln99dup
p.Gln99dup
p.Arg107Trp
p.Phe153Ser
p.Phe153Ser
p.Phe153Ser
p.Arg164Trp
p.Arg183Cys
p.Glu208Lys
p.Thr191_Phe193dup
p.Thr191_Phe193dup
CMT1B MPZ p.Ser78Leu
p.Ser78Leu
p.Tyr82Ser
p.Ser111Cys
CMT2I/J MPZ p.Asp109Glu
p.Thr124Met
p.Thr124Met
CMT2K GDAP1 p.Arg226Ser
p.Arg120Gly
CMT4A/ARCMT2K GDAP1 p.Met116Arg/p.Met116Arg
p.Arg120Trp/p.Met116Arg
p.Met116Arg/p.Met116Arg
p.Met116Arg/p.Glu145fs
p.Asp129His/p.Glu114fs
p.Gln99X/Gln99X
CMT4C SH3TC2 p.Arg954X/p.Arg1109X
p.Arg954X/p.Tyr1107X
p.Glu1005X/p.Arg1171Cys
CMT2A MFN2 p.Arg94Gln
p.Arg104Trp
CMT1D EGR2 p.Arg381His
p.Arg381His
CMT1F NEFL p.Pro22Ser
CMT2B RAB7 p.Val162Met
CMT2C TRPV4 p.Arg315Trp
CMT2F HSPB1 p.Gly84Arg
CCFDN CTDP1 p.Leu287fs
CMT, Charcot-Marie-Tooth; HNPP, hereditary neuropathy with sus-
ceptibility to pressure palsies. In bold are reported novel mutations
identified by our group.
population from a tertiary care neuromuscular center
in Campania, a region of Southern Italy. The detection
mutation rate was 75.1% and only four genes (PMP22,
GJB1, GDAP1, and MPZ ) accounted for 92% of all
genetically confirmed CMT cases (Table 2). This rate
is broadly comparable with that previously described
(Saporta et al., 2011; Murphy et al., 2012; Gess et al.,
2013; Sivera et al., 2013) and, especially, our four most
common genes correspond to those reported by Sivera
(Sivera et al., 2013). Instead, the group of the four
commonest genes includes MFN2 rather than GDAP1
in the studies of Gess (Gess et al., 2013), Murphy
(Murphy et al., 2012), and Saporta (Saporta et al., 2011)
(Table 2).
In demyelinating patients, CMT1A duplication was
by far the most common mutation detected both in
familial and isolated cases whereas the second gene
in order of frequency was MPZ (4.6%) in familial and
SH3TC2 (11.6%) in isolated cases.
The relatively high frequency of SH3TC2 muta-
tions that represents on the whole characterized CMT
population the fifth gene in order of frequency (2%)
was comparable with data reported by Murphy (1.6%)
(Murphy et al., 2012). Actually, Sivera (Sivera et al.,
2013) also found a high prevalence of SH3TC2 muta-
tions but the result was biased by the presence
of 26 Gypsy patients who harbored the SH3TC2
founder mutation (p.Arg1109X) associated with the
Gypsy population across Europe (Gooding et al.,
2005; Claramunt et al., 2007). All our CMT4C patients
presented with early and severe scoliosis that rep-
resents the most common clinical sign. However,
there was wide phenotypic variability. One patient
(carrying the p.Arg1109X/p.Arg954X mutations) was
wheelchair-bound, a second patient (carrying the
p.Tyr1107X/p.Arg954X mutations) presented with
marked contractures at upper limbs and the last one
(carrying the p.Glu1005X/p.Arg1171Cys mutations) had
a mild classical CMT phenotype.
Overall in CMT2 group, GJB1 was the most fre-
quent mutated gene and GJB1with GDAP1mutations
accounted for almost 3/4 of genetically defined CMT2
patients. Furthermore, the first gene in order of fre-
quency was GJB1 in familial and GDAP1 in isolated
cases.
CMTX is characterized by a great genetic variability
as more than 300 mutations have been described
in the GJB1 gene, and it is noteworthy that we
found 10 different mutations in 14 CMTX patients.
Moreover, two of these mutations consisted of small
insertions (p.Thr191_Phe193dup and p.Gln99dup) in
the coding region of GJB1 gene and to our knowledge
few in-frame insertions in the GJB1 gene have been
identified so far (http://www.hgmd.org/).
Mutations in the GDAP1 gene were found in 6
patients with autosomal recessive (AR) and 2 patients
with autosomal dominant (AD) inheritance. In 4 of
6 AR patients the p.Met116Arg recurred, probably
due to the described founder effect in Campania (Di
Maria et al., 2004). Additionally, we detected two AD
mutations (p.Arg226Ser and p.Arg120Gly) and one of
them resulted in the substitution of a highly conserved
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Table 2. Comparison of genetic distribution with other series.
Frequency, % (number of patients)
Present study n= 197 Sivera et al. n= 404* Gess et al. n= 589† Murphy et al. n=471‡ Saporta et al. n= 787
Characterized CMT
Overall 75.1 (148) 81.9 (331) 57.5 (339) 63.0 (297) 67.0 (527)
CMT1 85.3 (93) 95 (229) 66.0 (233) 80.4 (193) NA
CMT-I NA NA NA 59.7 (37) NA
CMT2 47.2 (26) 62.6 (102) 35.0 (53) 25.2 (29) NA
HNPP 87.8 (29) NA 64.0 (53) 67.3 (31) NA
Genes
PMP22# 72.3 (107) 56.1 (186) 69.9 (237) 69.0 (205) 65.0 (343)
GJB1 9.5 (14) 16.9 (56) 13.8 (47) 15.4 (46) 15.1 (80)
GDAP1 5.4 (8) 12.7 (42) 0 0.6 (2) 1.1 (6)
MPZ 4.7 (7) 5.7 (19) 6.1 (21) 4.3 (13) 8.5 (45)
SH3TC2 2.0 (3) 0.6 (2) 0 1.6 (5) 0.6 (3)
MFN2 1.3 (2) 1.2 (4) 3.5 (12) 4 (12) 4 (21)
CMT, Charcot-Marie-Tooth; HNPP, hereditary neuropathy with susceptibility to pressure palsies; NA, not applicable. Percentages and numbers
reported in bold indicate the four most common genes in each series of patients.
*Caucasian cases only (excluded Gypsy cases).
†Patients with sufficient nerve conduction studies.
‡Patients attending inherited neuropathy clinic; CMT-I, CMT intermediate.
#PMP22 duplication, deletion, and point mutations.
aminoacid at codon 120 that represents a mutational
hotspot for dominant GDAP1 forms (Claramunt et al.,
2005). As expected, patients with AR inheritance
presented with a severe phenotype with important
disability, whereas patients with AD GDAP1mutations
showed milder phenotype and intrafamilial variability
(Manganelli et al., 2012a).
Patients carrying autosomal dominant GDAP1
mutations are unequivocally classified as axonal CMT
(CMT2K), while it is still controversial the electro-
physiological classification of AR GDAP1 forms in
demyelinating (CMT4A) or axonal (AR-CMT2K) CMT.
In fact, patients with demyelinating, intermediate or
axonal nerve conduction studies have been reported.
Moreover, pathological findings from sural nerve biop-
sies include both axonal degeneration and myelin
abnormalities (Baxter et al., 2002; Senderek et al.,
2003; Sivera et al., 2013). In our study, NCS was con-
sistent with axonal pathology as the only nerves with
NCV in apparently demyelinating range were those in
which compound motor action potential was severely
reduced (<0.5mV). Accordingly, all ourGDAP1 patients
were classified on the basis of NCV as axonal CMT.
This is in keeping with Sivera et al. (Sivera et al., 2013)
that described 42 GDAP1 patients and found that in
these patients the neurophysiologic findings were
unequivocally axonal.
CMT series from Northern Europe (Murphy et al.,
2012; Gess et al., 2013) and the United States (Saporta
et al., 2011) report lower frequencies of GDAP1 muta-
tions than our own. Vice versa in those series, MFN2
has been identified as a common gene in axonal CMT,
while MFN2 mutations were rarely found in our study
(7.7% of CMT2).
The relatively higher frequency of GDAP1 over
MFN2 mutations is closer to data from the Span-
ish population, pointing out a possible influence of
geographical area (Mediterranean area) in genetic
distribution. However, a high frequency of MFN2
mutations has been recently reported in a cohort of
Italian CMT2 patients (Bergamin et al., 2014). In this
cohort, apart from two patients coming from Southern
Italy, the origin of the other CMT2A patients was
not reported. Thus, as all our patients came from a
well-defined geographical area, we might still support
the hypothesis of a possible geographical influence.
However, we cannot exclude that there might be some
bias beyond regional difference. Indeed, given the high
frequency of de novo MFN2 mutations and the wide
clinical variability (Bombelli et al., 2014), some patients
possibly harboring MFN2 mutations may not have
been suspected of having CMT disease and therefore
were not being directed to our reference center for
hereditary neuropathies.
In our cohort of patients we also identified a very
rare form of CMT. Among demyelinating patients we
found families carrying mutations in NEFL (CMT1F),
EGR2 (CMT1D), andCTDP1 (CCFDN) genes. Diagnosis
of CCFDN was suspected based upon peculiar clinical
features (congenital cataract, facial dysmorphism,
and demyelinating neuropathy) and Balcan gypsy
origin of family (Manganelli et al., 2013). Likewise,
among axonal patients the finding of ulcero-mutilating
neuropathy and vocal cord paralysis led to identify
mutations in RAB7 (CMT2B) and TRPV4 (CMT2C)
genes, respectively (Santoro et al., 2002; Manganelli
et al., 2012b).
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From our data it emerges that in demyelinat-
ing forms the diagnosis is achieved in most cases,
whereas in axonal forms more than half of the patients
remain without a molecular definition despite exten-
sive genetic screening. Accordingly, it can be assumed
that several other genes are still unknown, even though
it could be argued that not all known CMT genes were
tested in our cohort. However, 80 genes cause CMT
and so it is costly and time consuming to test all
known genes in every patient negative for the most
common genes. Therefore the high number of diag-
nostic failures requires a new genetic approach as
next-generation sequencing (NGS). On the other hand,
the high rate of diagnostic genetic success in HNPP,
achieved by only testing PMP22 gene, argues a limited
molecular genetic heterogeneity underlying HNPP.
Although our results are comparable to those from
larger CMT series, one limitation of this study could be
the smaller number of patients sampled, but they all
belong to a well-defined geographical area and it is not
our intent to extend these results to all South Italy.
Another limitation could be that we have not
considered, in calculating the distribution of gene
alterations, the intermediate CMT as a distinct elec-
trophysiological category. This may have influenced
our high frequency of GJB1 mutations in CMT2.
Indeed, the majority of our CMTX index cases were
classified as having axonal CMT according to upper
limb motor NCV, but more than 60% of these families
would be classified as having intermediate forms of
CMT disease. However, we think that when the aim
is the geographical distribution of CMT genes the
distinct cut-off criterion of 38m/s, leading to two main
electrophysiological categories, is more efficacious
and practical. Additionally, it is conceivable that the
high rate of GJB1 mutations in CMT2 group may also
depend on the high number of females (as index cases)
that, as expected, have more frequently NCV in axonal
range.
In conclusion, a rational diagnostic procedure in
evaluating a patient with CMT phenotype, in order to
optimize cost and time, and to increase the chance
of diagnostic genetic achievement, should take into
account the electrophysiological characterization, the
family history and, if already known, the genetic dis-
tribution in a defined geographical area. Therefore, the
epidemiological data we present here can help in panel
design for our patients’ population. The novelty of our
data is the relatively high frequency of SH3TC2 and
GDAP1 mutations in demyelinating and axonal forms,
respectively. Additional studies concerning genetic dis-
tribution are needed to evaluate whether this is only
a local feature or it can be expanded to the whole
Southern Italy and compared with other regions of the
Mediterranean area.
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